| Literature DB >> 26693352 |
Marius Papurica1, Alexandru Florin Rogobete1, Dorel Sandesc1, Raluca Dumache2, Radu Nartita3, Mirela Sarandan4, Alina Carmen Cradigati4, Loredana Luca5, Corina Vernic2, Ovidiu Horea Bedreag1.
Abstract
The critically ill polytrauma patient is a constant challenge for the trauma team due to the complexity of the complications presented. Intense inflammatory response and infections, as well as multiple organ dysfunctions, significantly increase the rate of morbidity and mortality in these patients. Moreover, due to the physiological and biochemical imbalances present in this type of patients, the bioproduction of free radicals is significantly accelerated, thus installing the oxidative stress. In the therapeutic management of such patients, multiple surgical interventions are required and therefore they are being subjected to repeated general anesthesia. In this paper, we want to present the pathophysiological implications of oxidative stress in critically ill patients with multiple traumas and the implications of general anesthesia on the redox mechanisms of the cell. We also want to summarize the antioxidant treatments able to reduce the intensity of oxidative stress by modulating the biochemical activity of some cellular mechanisms.Entities:
Year: 2015 PMID: 26693352 PMCID: PMC4674615 DOI: 10.1155/2015/238586
Source DB: PubMed Journal: Mol Biol Int ISSN: 2090-2182
Figure 1Schematic representation of oxidative stress in the critically ill patient with multiple traumas. Primary trauma induces a series of secondary injuries due to the biological and biochemical imbalances. The first side effect installed is SIRS, followed by sepsis, and finally by MODS. The inflammations generated by the action of the polymorphonuclear cells, as well as by hypermetabolism, maintain and enhance the oxidative stress. Mitochondria are significantly affected thereby producing significant amounts of superoxide anion. Free radicals produced at the cellular level are neutralized by the number of antioxidant enzyme systems, such as SOD, CAT, Trx, Gpx, and Prx [11, 12].
The most important endogenous antioxidant systems.
| Antioxidant system | Properties | Reference(s) |
|---|---|---|
| GSH | It is found in the extracellular environment as well as in the intracellular one | [ |
|
| ||
| Grx | It is part of the class thiol-disulfide oxidoreductases | [ |
|
| ||
| Trx | Redox activity occurs through the action on the disulfide bonds | [ |
|
| ||
| SOD | It is the main endogenous antioxidant system responsible for the inactivation of superoxide anion | [ |
|
| ||
| CAT | The main activity is the reduction of hydrogen peroxide to water and oxygen | [ |
|
| ||
| Prx | Reduced in general hydroperoxides | [ |
|
| ||
| PON | Extracellular oxidative enzyme | [ |
GSH: glutathione; Grx: glutaredoxins; Trx: thioredoxin; SOD: superoxide dismutase; CAT: catalase; Prx: peroxiredoxin; PON: paraoxonase; LDL: low density lipoprotein; HDL: high density lipoprotein.
Figure 2The chemical structure of (a) desflurane, (b) halothane, (c) isoflurane, (d) sevoflurane, (e) ketamine, (f) midazolam, and (g) propofol.
Figure 3The implications of general anesthetics in the cellular redox activity.
Figure 4Biogenesis mechanism for miRNAs. The synthesis of miRNAs begins in the nucleus with the action of RNA polymerase II on a protein-coding. This forms a first species, called pri-miRNA. Through successive reactions of polyadenylation catalyzed by DGCR8 and Drosa, the precursor for the miRNAs species, called pre-miRNA, is obtained. pre-miRNA thus formed is transported into the cytoplasm through Exportin 5. In the cytoplasm, on the pre-miRNA acts the Dicer complex. Subsequently through the action of TRBP, AGO2 and Dicer is obtained the RNA induced silencing complex (RISC) and finnaly the mature miRNAs.
miRNAs expression in patients who have received propofol.
| miRNAs | Expression | Reference(s) |
|---|---|---|
| miRNA-204, miRNA-92b, miRNA-30b, miRNA-127, miRNA-296-5p, miRNA-192, miRNA-26b, miRNA-25, miRNA-186, miRNA-191, miRNA-368, miRNA-194, miRNA-199a, miRNA-23b, miRNA-133a, miRNA-219-5p, miRNA-101, and miRNA-27a | Decreased | [ |
|
| ||
| miRNA-29b, miRNA-216a, miRNA-190b, miRNA-let-7c, miRNA-92a, miRNA-202, miRNA-140-3p, miRNA-198, miRNA-127-5p, miRNA-424, miRNA-193a-5p, miRNA-371-5p, miRNA-107, miRNA-296-3p, miRNA-143, miRNA-143, miRNA-let-7b, miRNA-30d, miRNA-302a, miRNA-103, miRNA-206-3, miRNA-153, miRNA-181d, miRNA-370, miRNA-134, miRNA-142-5p, miRNA-185, miRNA-1-let-7e, and miRNA-208b | Increased | [ |